Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Anaemia and Agranulocytosis Associated with Ticlopidine Therapy

Acta Haematol (1985) 73 (4): 232–234.
This article has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking.
Toxicity of thienopyridines on human neutrophil granulocytes and lymphocytes
  • Swarna Maseneni
  • Massimiliano Donzelli
  • Karin Brecht
  • Stephan Krähenbühl
Toxicology (2013) 308: 11.
Non-chemotherapy drug-induced agranulocytosis
  • Edeltraut Garbe
Expert Opinion on Drug Safety (2007) 6 (3): 323.
Safety, Tolerability, Pharmacokinetics, and Time Course of Pharmacologic Response of the Active Metabolite of Roxifiban, XV459, a Glycoprotein IIb/IIIa Antagonist, following Oral Administration in Healthy Volunteers
  • Henry J. Pieniaszek
  • Sherwin K. B. Sy
  • William Ebling
  • Michael J. Fossler
  • Valerie A. Cain
  • John T. Mondick
  • Su Ma
  • David M. Kornhauser
The Journal of Clinical Pharmacology (2002) 42 (7): 738.
Ticlopidine‐induced aplastic anemia: Two new case reports, review, and meta‐analysis of 55 additional cases
  • A. Symeonidis
  • A. Kouraklis‐Symeonidis
  • U. Seimeni
  • A. Galani
  • N. Giannakoulas
  • E. Fragopanagou
  • M. Tiniakou
  • P. Matsouka
  • N. Zoumbos
American Journal of Hematology (2002) 71 (1): 24.
Ticlopidine-Induced Lupus
  • Yolanda Braun-Moscovici
  • Daniel Schapira
  • Alexandra Balbir-Gurman
  • Ronit Sevilia
  • A. Menachem Nahir
JCR: Journal of Clinical Rheumatology (2001) 7 (2): 102.
Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: Case report and literature review
  • A. Taher
  • Z. Ammash
  • B. Dabajah
  • A. Nasrallah
  • F. H. Mourad
American Journal of Hematology (2000) 63 (2): 90.
Ticlopidine-Induced Severe Agranulocytosis After the Placement of Coronary Artery Stent
  • Ramazan Sari
  • Alper Sevinc
  • Suleyman Buyukberber
Angiology (2000) 51 (7): 591.
Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered IIb/IIIa Antagonist, in Patients with Acute Coronary Syndrome
  • Nishit B. Modi
  • William Novotny
  • James D. Reimann
  • Christopher P. Cannon
  • Eugene Braunwauld
The Journal of Clinical Pharmacology (1999) 39 (7): 675.
Pharmacokinetics and Pharmacodynamics of Sibrafiban (Ro 48-3657), an Orally Active IIb/IIIa Antagonist, Administered Alone or in Combination with Heparin, Aspirin, and Recombinant Tissue-Type Plasminogen Activator in Beagles
  • Nishit B. Modi
  • Yvonne S. Lin
  • Theresa Reynolds
  • Allison Shaheen
  • Brian J. Christian
Journal of Cardiovascular Pharmacology (1998) 32 (3): 397.
Pseudomonas Bacteremia Precipitated by Ticlopidine-Induced Neutropenia
  • Sandra M Geletko
  • Kathleen M Melbourne
  • Dennis J Mikolich
Annals of Pharmacotherapy (1996) 30 (3): 246.
Aplasie médullaire associée à la ticlopidine
  • JP de Jaureguiberry
  • M Galzin
  • P Talard
  • S Marlier
  • S Durupt
  • C Bouchiat
  • GV Dussarat
  • D Jaubert
La Revue de Médecine Interne (1996) 17 (12): 1032.
Acute interstitial nephritis associated with ticlopidine
  • Herman Rosen
  • Adel S. El-Hennawy
  • Sheldon Greenberg
  • Chun-Kuo Chen
  • Anthony D. Nicastri
American Journal of Kidney Diseases (1995) 25 (6): 934.
Ticlopidine and Fatal Aplastic Anemia in an Elderly Woman
  • Louise Mallet
  • Jacques Mallet
Annals of Pharmacotherapy (1994) 28 (10): 1169.
Bone marrow aplasia associated with ticlopidine therapy
  • Mazen Elias
  • Noga Reichman
  • Edith Flatau
American Journal of Hematology (1993) 44 (4): 289.
Agranlocytosis caused by ticlopindine and its mechanism
  • Kazutoshi Ono
  • Kazuhiro Kurohara
  • Masahiro Yoshihara
  • Yoshinori Shimamoto
  • Masaya Yamaguchi
American Journal of Hematology (1991) 37 (4): 239.
  • Online ISSN 1421-9662
  • Print ISSN 0001-5792
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal